Steve Kaf­ka joins Sec­tion 32 as man­ag­ing part­ner; Take­da auc­tions off $660M drug port­fo­lio in bid to re­duce post-Shire M&A debt load

→ For­mer Thrive CEO and part­ner at Third Rock Ven­tures, Steve Kaf­ka, has hopped aboard Sec­tion 32 as a man­ag­ing part­ner. With­in his new role, Kaf­ka “will fo­cus on sup­port­ing and ex­pand­ing the firm’s in­vest­ment port­fo­lio and pres­ence in Boston.” Cur­rent­ly, Kaf­ka serves as the ex­ec­u­tive chair­man at Thrive and at ArcherDX and he will con­tin­ue to serve with­in these roles. Kaf­ka’s pre­vi­ous stints in­clude roles as pres­i­dent and COO at Foun­da­tion Med­i­cine and serv­ing in po­si­tions at Aileron Ther­a­peu­tics, In­fin­i­ty Phar­ma­ceu­ti­cals, Mil­len­ni­um Phar­ma­ceu­ti­cals, Strate­gic De­ci­sions Group and For­rester Re­search.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.